These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

1. Supernus agreed to acquire SAGE for $12.00 per share in cash. 2. Deal valued at approximately $795 million, enhancing Supernus growth profile. 3. Analysts revised target prices for SAGE post-announcement, showing mixed sentiment. 4. SAGE shares rose 0.4% to $9.11 following the announcement. 5. Acquisition includes a non-tradable contingent value right up to $3.50.